吉利德将与Assembly Bio合作

C&EN Global Enterprise Pub Date : 2023-10-23 DOI:10.1021/cen-10135-buscon16

None Laura Howes

{"title":"吉利德将与Assembly Bio合作","authors":"None Laura Howes","doi":"10.1021/cen-10135-buscon16","DOIUrl":null,"url":null,"abstract":"Gilead Sciences is paying Assembly Biosciences $100 million for first refusal on all Assembly’s programs. The deal comprises $84.8 million in cash, plus $15.2 million in equity investment. Rather than buying the antiviral R&D firm outright, Gilead will integrate the company’s expertise in the herpes virus and hepatitis B and D. Assembly Bio will be responsible for early-stage research and development; if Gilead opts into any programs, it will take on all further work.","PeriodicalId":9517,"journal":{"name":"C&EN Global Enterprise","volume":"50 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Gilead to partner with Assembly Bio\",\"authors\":\"None Laura Howes\",\"doi\":\"10.1021/cen-10135-buscon16\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Gilead Sciences is paying Assembly Biosciences $100 million for first refusal on all Assembly’s programs. The deal comprises $84.8 million in cash, plus $15.2 million in equity investment. Rather than buying the antiviral R&D firm outright, Gilead will integrate the company’s expertise in the herpes virus and hepatitis B and D. Assembly Bio will be responsible for early-stage research and development; if Gilead opts into any programs, it will take on all further work.\",\"PeriodicalId\":9517,\"journal\":{\"name\":\"C&EN Global Enterprise\",\"volume\":\"50 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-10-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"C&EN Global Enterprise\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1021/cen-10135-buscon16\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"C&EN Global Enterprise","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1021/cen-10135-buscon16","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

吉利德科学公司向Assembly Biosciences公司支付了1亿美元，以获得Assembly公司所有项目的优先购买权。该交易包括8,480万美元现金，外加1,520万美元股权投资。吉利德不会直接收购这家抗病毒药物研发公司，而是将整合该公司在疱疹病毒、乙型肝炎和乙型肝炎方面的专长。Assembly Bio将负责早期研发;如果吉利德选择加入任何项目，它将承担所有进一步的工作。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Gilead to partner with Assembly Bio

Gilead Sciences is paying Assembly Biosciences $100 million for first refusal on all Assembly’s programs. The deal comprises $84.8 million in cash, plus $15.2 million in equity investment. Rather than buying the antiviral R&D firm outright, Gilead will integrate the company’s expertise in the herpes virus and hepatitis B and D. Assembly Bio will be responsible for early-stage research and development; if Gilead opts into any programs, it will take on all further work.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

C&EN Global Enterprise

自引率

0.00%

发文量